FS069 data

Animal data with the San Diego company's second-generation ultrasound contrast agent, FS069, were presented at the American Society of Echocardiography meeting in San Francisco, showing successful IV myocardial perfusion in dogs with mechanically induced flow restrictions.

In 10 dogs receiving FS069, which consists of proteinaceous microspheres, the agent was well tolerated, and gave statistically significant changes in opacity (p<0.0001) before and after flow restriction, compared to the period of restriction. No adverse events were seen, nor were any apparent in five other dogs given the agent, which produced myocardial opacity in a pattern that approximates myocardial perfusion, the company reported. ...